AVM-92

AVM-92 is an Avidin-developed oral multi-compound anticancer regimen comprising four anti-cancer compounds. Avidin describes the program as designed to exploit cancer-associated metabolic dependencies involving aerobic glycolysis, glutaminolysis, fatty-acid synthesis, pH regulation, and redox regulation. Preclinical activity was reported primarily in melanoma, breast cancer, and colon carcinoma, with minimal systemic toxicity reported by the developer; the individual components and direct molecular targets have not been publicly disclosed. ([avidinbiotech.com](https://avidinbiotech.com/avm-92-the-multicomponent-anti-cancer-molecule/))